A Randomised, Double Blind, Placebo-Controlled, Crossover Trial of Tetrahydrocannabinol and Cannabidiol for the treatment of Tourette’s Syndrome

Wesley Medical Research Insititute0 个研究点目标入组 22 人开始时间: 2018年4月12日最近更新: 2022年6月20日

试验速览

暂无简介。

•Confirmed diagnosis of Tourette's syndrome with a tic severity score greater than 20 on the Yale Global Tic Severity Scale.
•Must agree not to drive a motor vehicle during the trial.
•Able to give written and informed consent.

•History of epilepsy.
•History of multiple sclerosis.
•History of an additional movement disorder such as Parkinson's disease.
•History of dementia..
•Pregnancy and breastfeeding.
•Recreational cannabis smoker (participants must have a negative drug screen at study entry).
•Current treatment with deep brain stimulation.
•Current drug or alcohol abuse (excluding tobacco).
•Any history of psychosis.
•Diagnosis of bipolar disorder.
•History of any previous high-lethality suicide attempt, history of any suicide attempt in the last 12-months or at high-risk of suicide in the opinion of the screening clinician.
•Currently using antipsychotic or dopamine-depleting agents as treatment for Tourette's syndrome. Participants who have undergone a successful 4 week washout of current exclusionary therapies overseen by the Investigator will be eligible.
•Allergy to tetrahydrocannabinol and cannabidiol or the tablet excipients.
•Taken another study (experimental) drug within the past 30 days.

发起方

Wesley Medical Research Insititute